RIMS4 Antibody

What is RIMS4 and what role does it play in synaptic function?

RIMS4 (also known as RIM4 gamma or Rab3-interacting molecule 4) is a protein that regulates synaptic membrane exocytosis, playing a crucial role in neurotransmitter release at synapses . It belongs to the RIM protein family, which are key components of the presynaptic active zone, where they help coordinate synaptic vesicle docking and fusion. Unlike other RIM family members, RIMS4 has a more restricted expression pattern and likely serves specialized regulatory functions in specific neural circuits. Understanding RIMS4 function requires careful selection of antibodies targeting specific domains to distinguish it from other RIM family members.

What are the different forms of RIMS4 antibodies available for research?

RIMS4 antibodies are available in several configurations that serve different experimental purposes. Polyclonal antibodies raised in rabbits are most common, with varying target epitopes including N-terminal regions (AA 1-269 or AA 1-100) and internal regions . These antibodies come in multiple formats:

• Unconjugated antibodies for flexible application development

• Enzyme-conjugated versions (HRP) for enhanced detection sensitivity

• Fluorophore-conjugated antibodies (FITC) for direct visualization

• Biotin-conjugated versions for avidin-based amplification systems

The selection depends on your specific application, with each format offering different advantages for sensitivity, specificity, and multiplexing capabilities.

How should I select the appropriate RIMS4 antibody for my specific research question?

Selection should be guided by several experimental considerations. First, determine the species reactivity needed—many RIMS4 antibodies detect human and rat proteins, with some cross-reacting with mouse, pig, zebrafish, and other model organisms . Second, consider the application: Western blotting may require different antibody characteristics than immunohistochemistry or immunofluorescence. For example, antibody ABIN6264757 is validated for Western blotting and ELISA , while antibody A37759 is validated for Western blotting and immunohistochemistry . Third, evaluate the target epitope—N-terminal antibodies may detect different RIMS4 isoforms than those targeting internal regions. Finally, review validation data showing the antibody's performance in your intended application using tissues or cells similar to your experimental system.

What are the optimal protocols for using RIMS4 antibodies in Western blotting?

When using RIMS4 antibodies for Western blotting, researchers should implement the following methodology for optimal results. Begin with proper sample preparation: tissues or cells should be lysed in a buffer containing protease inhibitors to prevent degradation of RIMS4. For separation, use 10-12% SDS-PAGE gels, as RIMS4 has a molecular weight that requires appropriate resolution. Transfer conditions should be optimized for proteins in this molecular weight range (typically 30V overnight or 100V for 1-2 hours). For blocking, 5% non-fat dry milk or BSA in TBST is recommended to reduce background.

When applying the primary RIMS4 antibody, dilution ratios typically range from 1:500 to 1:1000, though this should be optimized for each specific antibody . Incubation should occur overnight at 4°C for maximum sensitivity. After washing, apply an appropriate HRP-conjugated secondary antibody (typically anti-rabbit IgG for most RIMS4 antibodies). Validation studies indicate that antibodies targeting the N-terminal region of RIMS4 tend to provide cleaner Western blot results with less non-specific binding.

What are the recommended immunohistochemistry procedures when using RIMS4 antibodies?

For immunohistochemistry applications with RIMS4 antibodies, tissue preparation is critical. Paraformaldehyde fixation (4%) is generally recommended, with careful optimization of antigen retrieval methods . Citrate buffer (pH 6.0) heat-induced epitope retrieval often works well for RIMS4 detection. Blocking should be performed with 10% normal serum from the same species as the secondary antibody to minimize background (e.g., normal goat serum for goat anti-rabbit secondary antibodies) .

Primary RIMS4 antibody incubation should occur overnight at 4°C at dilutions ranging from 1:100 to 1:500 depending on the specific antibody and tissue . For visualization, both chromogenic (DAB) and fluorescent detection systems are compatible with RIMS4 antibodies. When performing double or triple immunolabeling experiments, ensure that there is minimal cross-reactivity between the detection systems. RIMS4 antibodies have been successfully used to visualize expression in human breast carcinoma tissue and various neural tissues, with punctate staining patterns typical of synaptic proteins.

How can I optimize immunofluorescence protocols for RIMS4 detection?

For immunofluorescence applications, cell fixation methodology significantly impacts RIMS4 detection. The recommended protocol includes fixing cells in 4% formaldehyde followed by permeabilization with 0.1-0.3% Triton X-100 . Blocking should be performed with 10% normal goat serum to reduce non-specific binding. RIMS4 antibodies typically perform best at dilutions between 1:100-1:500 for immunofluorescence applications .

For co-localization studies with other synaptic proteins, sequential staining protocols may be necessary to avoid cross-reactivity. RIMS4 antibodies have been successfully used in MCF-7 cells as shown in validation studies . When performing multi-channel imaging, careful selection of fluorophores with minimal spectral overlap will improve signal discrimination. For quantitative analysis, standardization of image acquisition parameters is essential, including exposure time, gain settings, and z-stack parameters if performing 3D reconstruction of synaptic structures.

How can I address non-specific binding issues with RIMS4 antibodies?

Non-specific binding is a common challenge with RIMS4 antibodies that can be addressed through several methodological approaches. First, increase the stringency of your washing steps by using 0.1-0.3% Tween-20 in TBS/PBS buffers and extending wash durations to 15 minutes with 3-5 changes of buffer. Second, optimize your blocking solution—consider testing different blocking agents such as BSA, normal serum, or commercial blocking reagents at 5-10% concentrations. For tissues with high endogenous biotin, an avidin-biotin blocking step is essential when using biotin-conjugated RIMS4 antibodies .

If background persists, titrate your primary antibody concentration. While published protocols suggest dilutions from 1:100 to 1:1000, your specific sample may require further optimization . For immunohistochemistry applications, pre-adsorption of the antibody with the immunizing peptide (when available) can help determine if signals are specific. Finally, consider switching to a different RIMS4 antibody that targets a different epitope, as some regions may be more prone to non-specific interactions in certain experimental contexts.

What controls should be included in experiments using RIMS4 antibodies?

Rigorous experimental design requires multiple controls when working with RIMS4 antibodies. Primary antibody omission controls are essential to identify background from secondary antibody binding. Isotype controls (using non-specific rabbit IgG at the same concentration as the RIMS4 antibody) help distinguish between specific binding and Fc receptor interactions. Positive controls should include tissues or cells known to express RIMS4, such as neural tissues or MCF-7 cells as demonstrated in validation data .

For validation of specificity, consider including knockdown controls (siRNA or CRISPR) to demonstrate reduced signal with reduced RIMS4 expression. When available, blocking peptide controls (pre-incubation of antibody with the immunizing peptide) provide evidence of binding specificity. For quantitative applications, include calibration controls with known RIMS4 concentrations or expression levels. These comprehensive controls ensure that observed signals genuinely represent RIMS4 and not experimental artifacts.

How should I validate newly purchased RIMS4 antibodies before full experimental implementation?

Validation of new RIMS4 antibodies should follow a systematic approach before committing to large-scale experiments. Begin with Western blot analysis using positive control samples (neural tissues or cell lines known to express RIMS4) to confirm that the antibody detects a band of the expected molecular weight. Compare the results against published validation data, such as the Western blot results from JK and HeLa cells shown in product documentation .

Next, perform immunocytochemistry on fixed cells with known RIMS4 expression patterns to evaluate subcellular localization, comparing results to the punctate synaptic pattern expected for RIMS4. For tissue sections, start with positive control tissues (such as human breast carcinoma used in validation studies) before moving to experimental samples. Cross-validation with a second RIMS4 antibody targeting a different epitope provides additional confidence in specificity. Finally, where feasible, validate with genetic approaches by demonstrating loss of signal in RIMS4 knockdown or knockout systems.

How can RIMS4 antibodies be used to investigate synaptic protein complexes?

RIMS4 antibodies can be powerful tools for studying protein-protein interactions within synaptic complexes through several advanced methodologies. For co-immunoprecipitation (co-IP) experiments, use affinity-purified RIMS4 antibodies conjugated to solid supports (such as protein A/G beads) to pull down RIMS4 and its interacting partners from neural tissue or cell lysates. The immunoprecipitated complexes can then be analyzed by mass spectrometry to identify novel interaction partners or by Western blotting to confirm suspected interactions with other active zone proteins.

Proximity ligation assays (PLA) offer another sophisticated approach, where RIMS4 antibodies are used in conjunction with antibodies against potential interaction partners. This technique generates fluorescent signals only when proteins are within 40nm of each other, providing in situ evidence of molecular proximity. For higher resolution analysis, RIMS4 antibodies can be used in super-resolution microscopy techniques such as STORM or PALM to map the nanoscale organization of RIMS4 within the presynaptic active zone, revealing its spatial relationship with calcium channels and other exocytosis machinery components.

What are the considerations for using RIMS4 antibodies in primary neuronal cultures?

When applying RIMS4 antibodies to primary neuronal cultures, several methodological considerations become critical for success. Timing is essential—RIMS4 expression and synaptic localization are developmentally regulated, so experiments should be conducted after sufficient synaptogenesis has occurred (typically 14-21 days in vitro for rodent hippocampal or cortical cultures). Fixation protocols must preserve synaptic structure while maintaining epitope accessibility; 4% paraformaldehyde for 15 minutes at room temperature is typically effective .

For immunofluorescence in neurons, permeabilization requires careful optimization—0.1% Triton X-100 for 5-10 minutes usually provides sufficient access to synaptic proteins without disrupting structure. RIMS4 antibody dilutions often need to be higher for neuronal work (1:100-1:200) compared to cell lines . Co-labeling with synaptic markers such as synaptophysin (presynaptic) or PSD-95 (postsynaptic) helps confirm the synaptic localization of RIMS4 signals. For live-cell imaging applications, consider using fluorophore-conjugated RIMS4 antibody fragments that can access synaptic proteins in living neurons when applied to the culture medium.

How can RIMS4 antibodies be integrated into multiplexed proteomic approaches?

RIMS4 antibodies can be incorporated into advanced multiplexed proteomic workflows to understand synaptic protein networks comprehensively. For antibody microarray approaches, purified RIMS4 antibodies can be spotted onto array surfaces alongside antibodies against other synaptic proteins to enable parallel interrogation of multiple proteins from limited sample quantities. In mass cytometry (CyTOF) applications, RIMS4 antibodies conjugated to rare earth metals allow simultaneous detection of dozens of proteins at the single-cell level.

For spatial proteomics, RIMS4 antibodies can be employed in multiplexed ion beam imaging (MIBI) or CODEX systems, where antibodies are labeled with isotopes or barcoded oligonucleotides, respectively. These techniques permit visualization of dozens to hundreds of proteins in the same tissue section while preserving spatial information. When designing these experiments, consider epitope accessibility in the context of multiplexed staining, potential steric hindrance between antibodies targeting proximal epitopes, and the need for careful validation of each antibody in the multiplexed format to ensure signals remain specific and quantitative.

How should I interpret discrepancies in results between different RIMS4 antibody clones?

Discrepancies between different RIMS4 antibody clones are common and require careful analytical consideration. First, evaluate whether the antibodies target different epitopes—N-terminal (AA 1-269) versus internal region antibodies may recognize different RIMS4 isoforms or conformational states . This can be particularly relevant if post-translational modifications mask certain epitopes. Second, consider specificity differences—polyclonal antibodies typically recognize multiple epitopes and may show different cross-reactivity profiles compared to more targeted reagents.

Different validation methodologies may also contribute to apparent discrepancies. For example, A37759 was validated in human breast carcinoma tissue , while ABIN7167574 was validated in MCF-7 cells —these different cellular contexts may affect epitope accessibility or expression of RIMS4 binding partners. When facing discrepant results, perform side-by-side comparisons using identical samples and protocols, and consider implementing orthogonal approaches such as mRNA analysis or epitope-tagged expression systems to resolve the biological reality underlying antibody-based observations.

What should researchers consider when quantifying RIMS4 expression levels?

Quantification of RIMS4 expression requires rigorous methodological considerations to ensure accuracy and reproducibility. For Western blot quantification, always include a standard curve using recombinant RIMS4 protein when possible, or at minimum, ensure that measurements fall within the linear detection range of your imaging system. Normalization strategy is critical—for cellular studies, housekeeping proteins appropriate to the subcellular fraction being analyzed should be used, as RIMS4 is primarily localized to synaptic compartments.

For immunohistochemical or immunofluorescence quantification, standardize image acquisition parameters across all experimental groups and include fluorescence intensity calibration standards. When measuring synaptic RIMS4, co-labeling with synaptic markers allows normalization to synapse number, providing more meaningful data than raw intensity measurements. For comparative studies across brain regions or developmental timepoints, be aware that different RIMS4 antibodies may have varying affinities for different splice variants or post-translationally modified forms, potentially confounding interpretation of apparent expression differences.

How can RIMS4 antibody studies provide insights into neurological disorders?

RIMS4 antibody-based research has significant potential to illuminate mechanisms underlying neurological disorders involving synaptic dysfunction. Methodologically, this requires careful comparative studies between control and pathological tissues, with appropriate matching for age, post-mortem interval, and brain region. Quantitative immunohistochemistry can reveal changes in RIMS4 expression or localization in conditions such as epilepsy, autism spectrum disorders, or neurodegeneration where synaptic transmission is altered.

For mechanistic studies, RIMS4 antibodies can be used in combination with electrophysiological recordings to correlate RIMS4 expression or distribution with functional synaptic parameters. Co-immunoprecipitation with RIMS4 antibodies followed by mass spectrometry can identify disease-specific alterations in RIMS4 protein interactions. In genetic models of neurological disorders, RIMS4 immunolabeling can reveal how disease-causing mutations affect synaptic organization. These approaches collectively provide insights into how synaptic release machinery dysfunction contributes to neurological disease states, potentially identifying novel therapeutic targets for conditions involving aberrant neurotransmitter release.